InsidersTradesSigma
Total declarations
Companies
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
6
Disclosed sells
0
T+90 hit rate
60%
T+90 mean return
+10.8%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Schmid John P., Directeur. Director active across 5 companies, notably Xeris Pharmaceuticals INC. In total, 23 reports have been recorded. Split: 6 buys · 0 sell. Total volume traded: €77k. History available since 8 June 2022. The latest transaction was disclosed on 23 December 2025 (J). Regulator: SEC (Form 4). All data is openly available.
Declarations23 total
6,030 sharesCommon StockSEC:0001478916-26-000011:0
11,068 shares@ US$51.0062.9% of flowCommon StockSEC:0001478916-25-000004:0
6,030 shares0Common StockSEC:0001415889-25-017587:0
11,068 shares@ US$18.182224.4% of flowCommon StockSEC:0001415889-25-009100:0
21,692 shares@ US$4.5512.6% of flowCommon StockSEC:0001415889-25-001501:0
58,950 sharesCommon StockSEC:0001415889-25-001088:0
4,515 shares@ US$2.247420.2% of flowCommon StockSEC:0001867096-24-000176:0
Ideal exit: 9 May 2025 (T+270)
4,285 shares@ US$2.36520.2% of flowCommon StockSEC:0001867096-24-000173:0
Ideal exit: 6 May 2025 (T+270)
19,650 shares0Common StockSEC:0000950170-24-074875:0
3,900 shares0Common StockSEC:0001415889-24-017510:0
50,000 shares0Common StockSEC:0001867096-24-000110:0
5,400 shares@ US$1.9120.8% of flowCommon StockSEC:0001867096-24-000067:0
Ideal exit: 4 Feb 2025 (T+270)
9,156 shares@ US$3.6187100.0% of flowCommon StockSEC:0001415889-24-009063:0
Ideal exit: 17 Dec 2024 (T+270)
4,500 shares@ US$2.1619.3% of flowCommon StockSEC:0001867096-24-000034:0
Ideal exit: 9 Dec 2024 (T+270)
6,500 shares@ US$1.5119.6% of flowCommon StockSEC:0001867096-23-000147:0
Ideal exit: 12 Aug 2024 (T+270)
19,650 shares0Common StockSEC:0000950170-23-028607:0
42,500 shares0Common StockSEC:0001867096-23-000093:0
19,650 shares0Common StockSEC:0001209191-22-037667:0
15,000 shares0Common StockSEC:0001867096-22-000091:0
5,659 sharesCommon StockSEC:0000899243-21-039323
5,659 sharesCommon StockSEC:0000899243-21-039257:0
5,659 sharesCommon StockSEC:0000899243-21-039323:0
5,659 sharesCommon StockSEC:0000899243-21-039257
23 of 23 declarations
About Schmid John P.
John P. Schmid is a Director at Xeris Pharmaceuticals Inc, Xeris Biopharma Holdings, Inc., and Poseida Therapeutics, Inc. He participates in strategic decisions and oversees the activities of these companies. His experience in the pharmaceutical sector is valuable to the board.
